임신과 Coronavirus Disease 2019 백신
Coronavirus Disease 2019 Vaccination during Pregnancy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Several vaccines have been developed to combat the coronavirus disease 2019 (COVID-19), including messenger Ribonucleic acid (mRNA, Pfizer-BioNtech, and Moderna) and viral vector (AstraZeneca and Janssen) types. Unfortunately, reports of COVID-19 exposure during pregnancy are scarce, as pregnancy and breastfeeding were among the exclusion criteria in the efficacy and safety studies of major COVID-19 vaccines. The U.S. Centers for Disease Control and Prevention recently included pregnancy as a risk factor for severe COVID-19 infection, although the absolute risk is low. Previous experience in pregnant women with mRNA vaccines is lacking despite such vaccines not using live viruses, being unable to cause disease, not interacting with an individual's DNA, and being unable to cause genetic mutations. In addition, previous studies in animals have not revealed any safety issues with such vaccine types for female reproduction or fetal development. Vaccine-induced antibody titers were equivalent in pregnant and lactating women versus non-pregnant women. Given the data on increased mortality and morbidity associated with COVID-19 during pregnancy, it may be unethical to withhold vaccinations based on a theoretical risk and a lack of clinical research in this population. Additionally, a careful review of the vaccination recommendations for pregnant women by the academic community and government through additional efficacy and safety studies tailored to the situation in Korea is needed.
Abstract
Several vaccines have been developed to combat the coronavirus disease 2019 (COVID-19), including messenger Ribonucleic acid (mRNA, Pfizer-BioNtech, and Moderna) and viral vector (AstraZeneca and Janssen) types. Unfortunately, reports of COVID-19 exposure during pregnancy are scarce, as pregnancy and breastfeeding were among the exclusion criteria in the efficacy and safety studies of major COVID-19 vaccines. The U.S. Centers for Disease Control and Prevention recently included pregnancy as a risk factor for severe COVID-19 infection, although the absolute risk is low. Previous experience in pregnant women with mRNA vaccines is lacking despite such vaccines not using live viruses, being unable to cause disease, not interacting with an individual's DNA, and being unable to cause genetic mutations. In addition, previous studies in animals have not revealed any safety issues with such vaccine types for female reproduction or fetal development. Vaccine-induced antibody titers were equivalent in pregnant and lactating women versus non-pregnant women. Given the data on increased mortality and morbidity associated with COVID-19 during pregnancy, it may be unethical to withhold vaccinations based on a theoretical risk and a lack of clinical research in this population. Additionally, a careful review of the vaccination recommendations for pregnant women by the academic community and government through additional efficacy and safety studies tailored to the situation in Korea is needed.
참고문헌 (20)
- Breslin N, "Coronavirus disease 2019 in pregnancy : early lessons", Am J Obstet Gynecol MFM, 2, pp.100111~ (2020)
- Craig AM, "Coronavirus disease 2019vaccines in pregnancy", Am J Obstet Gynecol MFM, 3, pp.100295~ (2021)
- "Committee Opinion No. 400: COVID-19 and Pregnancy" (2020)[URL]
- Goh XL, "Incidence of SARS-CoV-2 vertical transmission : a meta-analysis", Arch Dis Child Fetal Neonatal Ed, 106, pp.112~113 (2021)
- Goldshtein I, "Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women", JAMA, 326, pp.728~735 (2021)
- Gray KJ, "Coronavirus disease 2019 vaccine response in pregnant and lactating women : a cohort study", Am J Obstet Gynecol, 225, pp.303.e1~303.e17 (2021)
- Halscott T, "Management considerations for pregnant patients with COVID-19", Society for Maternal-Fetal Medicine, ~ (2021)
- Kadali RAK, "Adverse effects of COVID-19 messenger RNA vaccines among pregnant women : a crosssectional study on healthcare workers with detailed selfreported symptoms", Am J Obstet Gynecol, 225, pp.458~460 (2021)
- Eun-Joong Kim, "코로나바이러스: 사스, 메르스 그리고 코비드-19", 대한임상검사과학회지, 52(4), pp.297~309 (2020), 대한임상검사과학회[DOI]
- Martins I, "EBCOG position statement on COVID-19 vaccination for pregnant and breastfeeding women", Eur J Obstet Gynecol Reprod Biol, 262, pp.256~258 (2021)
- Mullins E, "Pregnancy and neonatal outcomes of COVID-19 : coreporting of common outcomes from PANCOVID and AAP-SONPM registries", Ultrasound Obstet Gynecol, 57, pp.573~581 (2021)
- Oxford CM, "Trauma in pregnancy", Clin Obstet Gynecol, 52, pp.611~629 (2009)
- Rasmussen SA, "Coronavirus disease 2019(COVID-19)vaccines and pregnancy : what obstetricians need to know", Obstet Gynecol, 137, pp.408~414 (2021)
- "COVID-19 vaccination considerations for obstetric–gynecologic care" (2021)[URL]
- Sculli MA, "COVID-19 vaccination in pregnant and lactating diabetic women", Nutr Metab Cardiovasc Dis, 31, pp.2151~2155 (2021)
- "COVID-19 vaccine safety update. Advisory Committee on Immunization Practices (ACIP)" (2021)[URL]
- Shimabukuro TT, "Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons", N Engl J Med, 384, pp.2273~2282 (2021)
- Singhal T, "A review of coronavirus disease-2019(COVID-19)", Indian J Pediatr, 87, pp.281~286 (2020)
- Stafford IA, "The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations", Am J Obstet Gynecol, 224, pp.484~495 (2021)
- Wei SQ, "The impact of COVID-19 on pregnancy outcomes : a systematic review and meta-analysis", CMAJ, 193, pp.E540~E548 (2021)